ASCO GI 2025: BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic CRC from the Ph 3 BREAKWATER trial January 28, 2025
FDA Approves Lumakras® (Sotorasib) + Vectibix® (Panitumumab) For Chemorefractory KRAS G12C-Mutated Metastatic CRC January 21, 2025
Positive Update provided on Ph 2a Arm of IMM-1-104 in Combination with Modified FOLFIRINOX for 1L Pancreatic Cancer January 15, 2025
Invikafusp Alfa (STAR0602) Receives US FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic TMB-H CRC January 15, 2025
Supplemental NDA for cabozantinib in pNET and epNET patients no longer the subject of discussion at an ODAC meeting January 15, 2025
ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors January 15, 2025
China’s NMPA Approves VYLOYTM (zolbetuximab) for 1L Treatment of Advanced Gastric or GEJ Adenocarcinoma January 7, 2025
TEVIMBRA Approved in US for 1L Treatment of Gastric and GEJ Cancers in Combination with Chemotherapy December 31, 2024
EC approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with MSI-H or dMMR Metastatic CRC December 31, 2024
Positive Interim Ph 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer Announced December 26, 2024
Marker Therapeutics Awarded $9.5 Million Grant from the CPRIT to Support the Investigation of MT-601 in Patients with Pancreatic Cancer December 26, 2024
U.S. FDA Approves BRAFTOVI Combination Regimen as 1L Treatment of BRAF V600E-Mutant mCRC December 25, 2024
Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer December 18, 2024
Positive Initial Data from First-line RAS-mutated mCRC Ph 2 CRDF-004 trial evaluating onvansertib + SoC Announced December 18, 2024
Orphan Drug Designation from FDA for PLT012 in Treatment of Liver and Intrahepatic Bile Duct Cancer December 17, 2024
Relay Therapeutics & Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors December 10, 2024
First Patient Dosed in Ph 3 Clinical trial of HLX22/AC101 in 1L HER2-positive advanced gastric/GEJ cancer December 10, 2024
Outcomes of Type D meeting with FDA to obtain guidance on the design of a Ph 3 study of VCN-01 + chemo in metastatic pancreatic adenocarcinoma (PDAC) announced December 10, 2024
FDA Approves BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ NSCLC Based on Safety and Efficacy Data From the eNRGy Study December 10, 2024
Positive Topline Results from Ph 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Announced December 4, 2024
